Join the Tirzepatide group to help and get support from people like you.
Tirzepatide News
Most Slow Responders to Tirzepatide Do Lose Clinically Meaningful Weight
TUESDAY, May 14, 2024 – Among slow responders to tirzepatide treatment at week 12, 90 percent went on to achieve clinically meaningful weight reduction (≥5 percent) by week 72, according to a study p...
Aspiration Pneumonia Risk Increased for GLP-1 RA Users Undergoing Endoscopy
FRIDAY, April 12, 2024 – Patients using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) undergoing endoscopic procedures have an increased risk for aspiration pneumonia, according to a study...
Tirzepatide Improves 24-Hour BP in Obesity-Related Hypertension
WEDNESDAY, Feb. 7, 2024 – For patients with obesity and hypertension, tirzepatide improves 24-hour blood pressure (BP), according to a research letter published online Feb. 5 in Hypertension. James...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
Continuing Tirzepatide Leads to Maintenance of Weight Reduction
MONDAY, Dec. 11, 2023 – Withdrawing tirzepatide after 36 weeks is associated with regain of lost weight, while weight loss is maintained with continued treatment, according to a study published...
Tirzepatide Tied to Substantial Additional Weight Loss After Lifestyle Intervention
WEDNESDAY, Nov. 8, 2023 – Tirzepatide provides substantial additional reduction in body weight in participants who already achieved ≥5.0 percent weight reduction with an intensive lifestyle i...
FDA Approves Zepbound (tirzepatide) for Chronic Weight Management
INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity t...
Wegovy, Ozempic Help Folks Lose Weight, But How?
TUESDAY, Oct. 10, 2023 – As many doctors and patients hail the advent of weight-loss drugs like Ozempic and Wegovy as the perfect fix for obesity, some experts are urging caution. The drugs are not...
Reductions Seen in HbA1c, Body Weight With Once-Weekly Tirzepatide
FRIDAY, Oct. 6, 2023 – For patients with inadequately controlled type 2 diabetes, once-weekly subcutaneous injections of tirzepatide yield reductions in hemoglobin A1c (HbA1c) and body weight...
Tirzepatide Bests Semaglutide for Patients With Type 2 Diabetes
THURSDAY, Oct. 5, 2023 – Tirzepatide is superior to semaglutide for both blood sugar control and weight loss among people with type 2 diabetes, according to research presented at the European...
Diabetes Drug Maker, Sues Over Compounded Versions of Mounjaro
WEDNESDAY, Sept. 20, 2023 – Another diabetes drug maker is taking legal action against businesses in several states, alleging that they’re “fraudulently claiming” that their compounded products are t...
American Diabetes Association, June 23-26
The annual meeting of the American Diabetes Association was held this year from June 23 to 26 in San Diego and attracted more than 15,000 participants from around the world, including clinicians,...
ADA: Once-Weekly Tirzepatide Leads to Weight Loss in Patients With Obesity, T2D
TUESDAY, June 27, 2023 – Once-weekly tirzepatide provides substantial and clinically meaningful reductions in body weight in adults with obesity and type 2 diabetes, according to a study published...
FDA Approves Mounjaro (tirzepatide) Injection for the Treatment of Adults with Type 2 Diabetes
INDIANAPOLIS, May 13, 2022 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Diabetes, Type 2